Collaboration Targets Sample Clauses
The Collaboration Targets clause defines specific goals or benchmarks that parties in an agreement aim to achieve together. Typically, this clause outlines measurable objectives, such as project milestones, performance metrics, or deliverable deadlines, which both parties are responsible for meeting during the course of their collaboration. By clearly establishing these targets, the clause ensures mutual understanding of expectations and provides a basis for evaluating progress, thereby reducing ambiguity and helping to prevent disputes over performance.
Collaboration Targets. Except as may be expressly stated to the contrary in this Agreement under Article 12 or in Section 5.7.2, and except as expressly authorized under the provisions of this Agreement and as necessary to perform its obligations hereunder, ChemoCentryx hereby covenants that it shall not, either alone or with/for any Third Party: with respect to each Collaboration Target, during the period commencing on the Effective Date and ending on the first anniversary of the last day of the Research Term, as may be extended (the “Research Exclusivity Period”), conduct any research or development activities or grant any license or other rights with respect to the identification or optimization of small molecule antagonists (or agonists as applicable) of any Collaboration Targets. Following the end of the Research Exclusivity Period, with respect to any Collaboration Target which is the subject of any Early Development Program being drafted under the auspices of the JSC or then underway, ChemoCentryx also hereby covenants that it shall not, either alone or with/for any Third Party: with respect to each such Collaboration Target, conduct any research or development activities or grant any license or other rights with respect to the identification or optimization of small molecule antagonists (or agonists, as applicable) of any Collaboration Target(s) unless and until the earlier of (i) exercise by GSK of its last Product Option with respect to all of such Early Development Programs directed against such Collaboration Target, or (ii) the termination of all Early Development Programs with respect to such Collaboration Target (the “Development Exclusivity Period”). It being understood and agreed however, that after the end of the Research Exclusivity Period for those Collaboration Targets as to which at such time there is no Early Development Program either being drafted under the auspices of the JSC or then underway, and after the end of the Development Exclusivity Period for those Collaboration Targets as to which there is an Early Development Program, ChemoCentryx shall have the right, alone or with a Third Party, to conduct any research and development activities with respect to such Collaboration Target, including for example the rescreening of compounds against such Collaboration Target, subject at all times to GSK’s rights under Article 4 and to the covenant under Section 7.2, and GSK’s rights pursuant to any Product Options.
Collaboration Targets. Neither Party may engage in any research and development activities with respect to a Collaboration Target with any Third Party or independently outside of the Collaboration during the applicable Exclusivity Period, provided that the foregoing shall not prohibit a Party from engaging a subcontractor pursuant to Section 18.15 to perform certain of its obligations hereunder. The “Exclusivity Period” shall mean the period starting when a particular Collaboration Target is accepted into the Collaboration, and shall continue for the longer of: (a) […***…], (b) […***…], or (c) […***…]. For the avoidance of doubt, Ambit shall be free to continue to provide its screening services (similar to those provided under the Profiling Services Agreement) to Third Parties.
Collaboration Targets. All Collaboration Targets shall become Discontinued Targets; and
Collaboration Targets. The Parties acknowledge that CK's technology with respect to the Mitotic Kinesin Targets and the research conducted under the Research Program could potentially provide a large number of Mitotic Kinesin Targets and Compounds on which to focus further research and development activities, and that, under the collaboration, the Parties will focus their resources on particular Mitotic Kinesin Targets to be selected by GSK as Collaboration Targets in accordance with this Section 2.7.
Collaboration Targets. Carisma’s obligations under ARTICLE IV shall continue for [**] after the termination of this Agreement, and on the expiration of such [**] period all Collaboration Targets shall become Discontinued Targets; and
Collaboration Targets. In consideration of the options and licenses granted by Ambit hereunder to Collaboration IP and Ambit IP, the sum of […***…]. Other than the milestone and royalty payments set forth in Article VIII, no further payments shall be due to Ambit from Cephalon, unless the Parties mutually agree to change the Collaboration or to extend the Collaboration Term pursuant to Section 16.2.
Collaboration Targets. GSK shall have the right to extend the Research Term on an annual basis for up to three (3) additional one-year periods beyond Contract Year Five. To exercise such option, GSK shall so notify CK in writing at least [*] ([*]) months prior to the expiration of the Research Term (including any extensions thereof in accordance with this Section 2.8.1). During any extension of the Research Term under this Section 2.8.1, the Research Plan shall provide for [*] ([*]) CK FTEs, or a higher number if mutually agreed, performing activities with respect to Collaboration Targets under the Research Program, funded by GSK at the FTE rate established under Section 6.2.1 below. It is understood that, during any extension under this Section 2.8, the Research Program shall be limited to research and development activities directed to Collaboration Targets, except as provided under Section 2.8.2 below. In the event that the Research Term ends at any point in time, * Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. then from and after such time GSK shall have no further right to extend the Research Term under this Section 2.8.1.
Collaboration Targets. Lilly may select and replace Collaboration Targets pursuant to this Section 4.2. The number of Collaboration Targets under active Research at any given time shall be: (a) no fewer than [* * *] during each of the first [* * *] of the Research Term; and (b) no more than [* * *] at any time during the Research Term.
Collaboration Targets. (i) BMS has the right to designate up to three (3) Collaboration Targets for the Research Program in accordance with this Section 3.3(c). Any Collaboration Target designated by BMS shall be selected based on being a suitable target for the treatment of one or more oncology indications in the Field. As of the Effective Date, two (2) Collaboration Targets for which Compounds will be pursued in accordance with the initial Research Plan. Exhibit H identifies the 2 Collaboration Targets designated as of the Effective Date. The initial Research Plan is attached as Exhibit E and describes the work to be conducted in connection with these 2 Collaboration Targets.
(ii) In addition, BMS will have the right to designate a third Collaboration Target within 2 years of the Effective Date, in accordance with and subject to the Excluded Target Procedure described below in this Section 3.3(c). In advance of work being initiated by the Parties with respect to such third Collaboration Target, the JRC shall update the Research Plan to include work on such third Collaboration Target, with the Research Plan expected to be similar in scope and FTE effort as specified for either of the first two (2) Collaboration Targets under the initial Research Plan.
(iii) In addition, during the Research Term, BMS (through the JRC) shall be able to substitute and replace any of the initial or then-current Collaboration Targets with up to a maximum of three (3) new Targets (a “Replacement Target”) in accordance with and subject to the Excluded Target Procedure described below in this Section 3.3(c), provided that (x) any such replacement of a Collaboration Target must occur prior to the start of a Phase I Clinical Trial of a Compound for such Collaboration Target; (y) except in the case described in the following clause (z), any such replacement of a Collaboration Target must be based on new technical/scientific information concerning the safety and/or efficacy relating to the Collaboration Target, based upon which BMS reasonably determines that the Collaboration Target is no longer attractive to pursue (for example, the failure of a Compound to meet success criteria in efficacy model(s) or in a non-human primate toxicology study); and (z) BMS may replace the third Collaboration Target for any reason prior to work being initiated under the Research Plan for such Collaboration Target. In the case where BMS desires to replace an existing Collaboration Target with a proposed Replacement Target, B...
Collaboration Targets. Each Eligible Collaboration Target shall be determined upon exercise of the Co-Funding Option by Sunesis for a Product directed at a Collaboration Target, whereupon such Collaboration Target shall be deemed an Eligible Collaboration Target. It is understood that there may be more than one (1) Co-Funded Product directed at a single Eligible Collaboration Target.